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Abstract The term “neuroprotection” is often misused,
overused, or misunderstood. A reasonable definition of neu-
roprotection refers to the preservation of “neuronal structure
and/or function.” Although our knowledge about the cellular
and molecular mechanisms of neurodegeneration has expand-
ed, experimental systems and animal models that mimic the
process or allow translation into clinical success remain lim-
ited. This editorial discusses reasons for this gap and strategies
to close it. Experimental models can only mirror certain as-
pects of disease mechanisms in humans. Therefore, findings
in these models need to be linked with patient data to improve
real-life relevance. Successful neuroprotection depends on find-
ing the right “window of opportunity” which varies from very
short (stroke) to very long (Alzheimer’s disease), necessitating
the need to focus on strategies for very early disease recogni-
tion. This need challenges the strategies to be chosen, trial
approaches and methodologies, and the allocation of resources.
Additionally, outcome measures are often not well suited to
assess neuroprotection. To this end, surrogate measures, includ-
ing biomarkers, are useful endpoints to demonstrate evidence
of target directed therapeutic utility. Finally, studies have shown
that neuroprotection is not likely to succeed when targeting
only one pathway. These obstacles have reduced the level of
enthusiasm for neuroprotection in certain disease areas (e.g.,
stroke). Academia, industry, regulatory authorities, funding
agencies and patient organizations have to cooperate to a great-
er extent in order to overcome these impediments and to en-
courage nonclassical concepts. These concepts will be interdis-
ciplinary in order to achieve meaningful disease modification.
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Neuroprotection is certainly among the most desirable
therapeutic goals in many major neurologic disorders
[e.g., multiple sclerosis (MS), stroke, Alzheimer’s disease
(AD), Parkinson’s disease (PD), chronic epilepsy). The
term “neuroprotection” is commonly understood as a
means of preventing neuronal damage over short or lon-
ger time periods. Within this, prevention, rescue and re-
pair mechanisms can be distinguished, all having a
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potential impact on neuronal survival over time. While
decades of research efforts have been dedicated to this
goal, the overall therapeutic success in various clinical
trials across neurologic disease entities is deplorably lim-
ited. Even though there are common features among dif-
ferent diseases and pathogenic mechanisms, the definition
of clinical Bneuroprotection^ in each individual condition
remains difficult. This editorial considers a number of
ideas as to why such a gap exists between the increasing
knowledge of molecular and cellular mechanisms of neu-
rodegeneration and neuroprotection in experimental sys-
tems and the translation into clinical success. Reasons are
manifold and include: 1) major difficulties regarding the
standardization of experimental model systems supposed
to mimic the pathogenesis of neurologic disorders; 2)
missing the window of opportunity for therapeutic inter-
vention; 3) inappropriate or unfocused selection of patient
populations (often combining rather heterogeneous groups
mostly based on mere clinical but not biological criteria);
4) inappropriate choice of outcome measures (Appendix
Table); 5) traditional clinical trial designs and non-adaptive
methodologies; and 6) lack of sufficient funding as neuropro-
tective trials, in general, last years longer than the standard
period of a pivotal registration trial for symptomatic therapies
in the abovementioned disorders.
While major progress in the definition of molecular or cel-
lular markers has been made, finding the appropriate window
of opportunity for clinical trials has turned out to be a formi-
dable task. This notion has long been obvious in diseases with
underlying short-acting, hyperacute, or acute neuronal dam-
age as neurotrauma. Closure of a therapeutic window may
also be a critical determinant in chronic neurodegenerative
disorders such as AD and PD. Converging evidence suggests
an onset of pathological processes years or decades before the
manifestation of the first subtle clinical signs and symptoms
emerge. In this circumstance, attempts at therapeutic neuro-
protection are then initiated too late for an effective disease
modification.
In MS, immune-mediated inflammation and neurode-
generation are key pathologic features. Their contribution
to disease pathology and outcome differs between stages
and phases of the disease. Early (and earliest) interven-
tions with several immune-therapeutic agents in relapsing
forms of MS have shown significant benefit with regard
to disease modification by reducing inflammatory activity
(relapse rates, evidence of inflammatory lesion activity on
imaging studies) and in parallel aspects of neurodegener-
ation (e.g., disability progression, T1 hypointense lesions
on magnetic resonance imaging, development of cerebral
atrophy) [1, 2]. However, trials aimed primarily at modi-
fying disease progression (in primary progressive or sec-
ondary progressive MS) have been largely unsuccessful
so far. Conceptual Bdirect^ and Bindirect^ neuroprotective
approaches need to be dis t inguished, the lat ter
representing the dominating feature of current immune
therapies.
Taking the various aspects and experiences into consid-
eration, perspectives and challenges for future trial de-
signs to prove “prevention of neuronal damage” in neuro-
logic disorders appear obvious. Heterogeneity of study
populations needs to be better controlled. Integrating
paraclinical surrogate measures or biological information
(including biomarkers) will help to stratify patients. Ad-
ditionally, adaptive study designs, less conventional,
multiparametric assessments and endpoints that compre-
hensively and sensitively capture the varied consequences
of the neurodegenerative pathobiology on disease activity
and progression will have to be considered. Further,
multidomain, as well as population-based, approaches
with risk-enrichment strategies are required in certain dis-
ease areas, leading to rather novel methodological ap-
proaches for trial approaches. We recommend substituting
the often misconceived term Bneuroprotection^ with a
more pragmatic description such as Bprevention of neural
damage^.
How Should we Define BNeuroprotection^?
Very few terms have been more overused, misused, or even
misunderstood in clinical neuroscience over the years than
Bneuroprotection^. Specifically, assumptions as to how this
Bneuroprotection^ could possibly modify the outcome of cer-
tain neurologic disorders have been unrealistic. A reasonable
definition of neuroprotection refers to the relative preservation
of neuronal structure and/or function [3, 4]. More generally,
and applied to a variety of neurologic diseases, the aim is to
prevent neuronal damage over time (either acute or chronic).
The traditional assumption is that the course or outcome of
many central nervous system disorders, including disorders
associated with acute neuronal damage and chronic neurode-
generation (traumatic brain injury, stroke, MS, AD, PD, etc.),
can be modified via exploiting Bneuroprotective^ mecha-
nisms. Based on current concepts of key effector mechanisms
of neuronal damage in the above disorders, experimental treat-
ments often consider targeting oxidative stress, cytotoxicity,
or a combination of both, providing direct neuroprotection
versus indirect neuroprotection through modification of vari-
ous collateral mechanisms involving inflammation. Finally,
the term neuroprotection is, unfortunately, often misused by
industry marketing strategies for advertising agents, with rath-
er questionable potential. From the pragmatic point of view of
patients and physicians, Bneuroprotection^ means keeping
neuronal and glial damage under the threshold of symptom
manifestation.
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How do we Standardize BNeuroprotective^ Approaches
and Outcomes of Experimental Models Mimicking
Aspects of Neurological Diseases?
Experimental models of neurodegenerative disorders (models
of stroke, MS, experimental autoimmune encephalomyelitis,
AD, PD, epilepsy etc.) always reflect only certain aspects of
the clinical disease. Scientifically, it is appropriate to make
extrapolations and cautiously point out analogies of molecu-
lar, subcellular, cellular, or systemic alterations in experimen-
tal models to human disorders. However, comparability and
standardization of experimental model systems across labora-
tories is a goal that should be achieved before preclinical data
are accepted to be taken into a clinical research program [5].
Even after this problem with experimental systems is resolved
with rigorous multicenter standardizations, models can only
mirror certain aspects of usually multifaceted disease mecha-
nisms in humans. Several groups are now trying to define
criteria for how experimental standards should be adjusted to
increase the likelihood of obtaining relevant findings in those
models, and to make them more plausible or to translate them
into proof-of-concept clinical trials. Obviously, such measures
may increase the reliability of experimental models, raising
the hope that this may aid in a faithful translation to the clinical
realm, but still cannot provide statistical probability of poten-
tial outcome success in human diseases. Prudent use of exper-
imental models takes into consideration the notion that these
may replicate human disease only partially both in terms of
categories of pathobiology and temporal evolution. Therefore,
findings in these models need to be linked with patient data to
improve real-life relevance. In other words, human data from
pathological and nonpathological controls need to be integrat-
ed in order to evaluate and potentially validate findings in
animal models.
Are we Approaching the Right BWindow of Opportunity^
in the Target Diseases?
Epidemiologic, pathophysiologic, and clinical trial data
have clearly demonstrated that there are limited windows
of opportunity or time lines for the therapeutic modifica-
tion of neuronal damage, which are specific for every
disease. The best-known scenarios for acute diseases with
a very small window of opportunity are stroke, and trau-
matic brain and spinal cord injury. Here, myriads of un-
successful trials of applying neuroprotection have empha-
sized the existence of and the need for defining a “win-
dow of opportunity” (e.g., thrombolysis). Agents pre-
sumed to interfere with such acute/hyperacute mecha-
nisms need to be administered as early as possible to
attain efficacy. It still remains doubtful whether ap-
proaches targeting single pathways or molecular
structures are at all capable of influencing such a dramatic
cascade of multiple events leading to acute cell death due
to the hypoxic/excitotoxic nature of the acute event. Here,
neural repair and strategies to promote neuronal plasticity
after acute damage are certainly complementary to the
primary aim of preventing neuronal damage. Naturally,
disorders such as AD and PD need to be considered on
the other, chronic, end of the spectrum. Prodromal pheno-
types—such as rapid eye movement sleep behavior disor-
der in the case of PD or social withdrawal in the case of
AD—can be observed before the threshold for the classi-
cal clinical syndrome is reached [6–8]. Therefore, we
need to think more in terms of very early recognition,
intervention, or even prevention strategies. These would
impose enormous challenges on strategies to be chosen,
trial approaches, and methodologies to be implemented
and, therefore, risk taking on the allocation of available
resources of scientific personnel and funding. In MS, sev-
eral examples have now clearly demonstrated that highly
active, anti-inflammatory agents (e.g., the monoclonal an-
tibodies natalizumab and alemtuzumab, or new immune
therapeutic small molecules such as the first-in-class
sphingosin 1 phosphate receptor modulator fingolimod)
are quite effective in influencing disease activity, both in
terms of relapse frequencies and disability progression.
The therapeutic efficacy has even prompted definition of
new outcome measures such as Bno evidence of disease
activity ,^ Bno evidence of disease activity including ongo-
ing atrophy ,^ or Bfreedom of disease^ [9]. However, in
trials of primary and secondary progressive MS, strategies
arguably work in relapsing forms of disease show—to a
certain extent—reduction of inflammatory aspects of the
disease but no clinically significant improvements on dis-
ability progression as a measure of ongoing and cumula-
tive neurodegeneration [10, 11]. This clearly advocates
the concept of a “window of opportunity” to prospectively
prevent progression in MS. It does not resolve the problems
of individuals who have started as primary progressive or
who are entering the phase of secondary progression, de-
spite therapeutic interventions with drugs for the relapsing
remitting phase of the disease [12].
Are we Using Appropriate Outcome Measures?
Recent years have shown that the choice of primary and sec-
ondary end points for several diseases in respective clinical
trials is challenging [13]. Regulatory authorities are often rigid
in their views regarding which outcome measures have to be
used and how. A standard requirement of importance relates to
sensitivity to capture change and whether this is clinically
meaningful. It is true that some of these outcome measures
are hard to standardize, quite reductionist, sometimes almost
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1-dimensional. Efforts to establish accepted alternative out-
come measures and demonstrate their increasing utility in
the absence of comparative studies have followed a rocky
path. An example in place is the expanded disability status
scale (EDSS) in MS, the most commonly used score to assess
disability and its progression. Despite the obvious and multi-
fold limitations (including high inter-rater variability, ordinal
nature, and the limited focus on walking capability above
values of 4.0), none of the alternative measures has reached
a reasonable level of acceptance and broad usage in the MS
trial community. This leads to continued use of and reliance on
EDSS as the preferred outcome measure to assess disability in
MS. MS has seen undisputed success stories over the last 2
decades, but also numerous failed trials of agents aiming at
targeting neurodegeneration [1, 14, 15]. It should be noted that
clinical trials have strict diagnostic criteria that are often de-
pendent on elements characteristic of late disease, a clear im-
pediment to studying neuroprotection. New vistas and ways to
measure neuroprotection are necessary. Surrogate measures,
including imaging markers (magnetic resonance imaging,
positron emission tomography, single-photon emission com-
pu ted tomography) , b iomarke r s f rom di f f e ren t
biocompartments, or different stratification approaches (bio-
logical, genetic, clinical, etc.), are often not integrated or con-
sidered. Specifically, with regard to proof-of-concept assess-
ments, more domains and adaptive, flexible trial designs are
necessary for better stratified approaches. Some of the more
modern phase II trial designs have been or are developed in
this direction [16, 17]. It should be acknowledged that con-
founding environmental and genetic factors have a high im-
pact on neuroprotection but are very hard to define and/or to
control. The growing field of different Bomics^ and system
biology approaches will provide possible algorithms to inte-
grate this knowledge into therapeutic approaches. One key
issue will be to integrate regulatory authorities closely in the
process of developing new end points for Bneuroprotection
trials^.
Taking MS as a paradigm, lessons for the future also con-
cern the limitations of included study participants: many stud-
ies simply suffer from an enormous heterogeneity of the pa-
tient population enrolled, mostly based on rather superficial
clinical criteria, while neglecting additional underlying bio-
logical surrogate information. To achieve more homogenous
cohorts, inclusion information should be broader and supple-
mented by surrogate and/or biomarkers (e.g., cerebrospinal
fluid, peripheral blood, optical coherence tomography, etc.).
Also, with regard to trial design, realistic assumptions have to
be made in terms of power calculations, trial durations (at least
36 months in MS for meaningful phase III trials to assess
influence on neurodegeneration). For phase I and phase II
trials, surrogate measures should certainly be allowed as help-
ful end points to demonstrate evidence of target directed ther-
apeutic utility.
Challenges, Approaches and Perspectives for Future Trial
Designs to Measure Brain Protection or Prevention
of Brain Damage
As alluded to above,multiple clinical trials aimed at protecting
neurons and the neural parenchyma in neurologic disorders
have more often failed than provided evidence for therapeutic
efficacy. The reasons for this are numerous, but especially
regarding trial design and choice of outcome measures, a
number of lessons have been learned and should guide future
drug developments [13].While nobody will disagree that clin-
ical outcomes with patient-relevant measures are certainly
most achievable, a number of these outcome measures lack
both sensitivity and standardization. Integration of clinical and
paraclinical measures might be one way to overcome these
limitations. At least objective surrogates may help to better
understand the influence of therapeutic interventions on as-
sumed pathogenic mechanisms and measurable outcomes. Al-
though there are certainly commonalities among different dis-
eases with respect to the difficult aim of assessing brain pro-
tection and preventing brain damage, major differences exists
in their underlying pathogenic mechanisms, disease courses,
and individual patient factors. Therefore, only certain aspects
within a harmonized approach to achieve brain protection in
several neurologic disorders can be generalized, such as the
call for standardization and better evaluation of experimental
models mimicking aspects of the disease. In terms of clinical
trials, it is required to define both the standards of outcome
measures, the integration of modern and traditional surrogate
measures, and the sequence of phase I to phase III (with partly
adaptive) trial designs. Very chronic neurodegenerative disor-
ders, especially AD and PD, probably have a higher likelihood
for success with extremely early, biomarker-based, or even
preventive, strategies using risk-enrichment selection criteria
(e.g., family, genetics, biomarkers, prodromal symptoms). For
MS, a field that has highly benefitted from recent repeat suc-
cesses of therapies targeting inflammation, the unmet need to
affect disease progression, as the most likely consequence of
continuing neural damage, remains unresolved. Recently, a
large trial in primary progressive MS using fingolimod, a sub-
stance working both in the peripheral immune system and in
the central nervous system [18, 19], has shown no clinical
benefit in a modern, multiparametric, multidomain outcome
measures trial over 3 years [20]. The reasons for this failure
remain to be determined. One general conclusion would be
that there is a low likelihood of success targeting one pathway
or one selective mechanism within a rather heterogeneous,
nongenetically determined condition operative over many
years. One example for such a Bfailed^ strategy is the defini-
tion of secondary progression as a homogenous disease stage
of MS. Secondary progression may have various reasons: it
may result from multiple preceding, interlinked, or
noninterlinked, dependent or independent pathogenic
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mechanisms. The term eventually leads into a “melting pot” of
progressive disease forms with different Bflavors^ [21]. This
would raise the possibility that in progressive forms of MS
combination treatment approaches could attain a more prom-
inent role, addressing and tackling several bona fide candidate
pathways at the same time.
In summary, prevention of neuronal damage (“neuro-
protection”) remains the holy grail of disease modifica-
tion in several major neurologic disorders. Recent years
have clearly diminished the level of enthusiasm for direct
neuroprotection in certain disease areas (e.g., stroke) but
have refined the definition of treatment goals, which pre-
vent neuronal damage, either directly or indirectly. The
emerging field of elucidating and better defining disease
heterogeneity with the integration of surrogate markers,
biomarkers, genetics, epigenetics, and system biology ap-
proaches in conjunction with novel clinical trial designs
and methodologies currently open up new avenues.
Within this Bprevention strategies^, risk enrichment,
stratification, and selection strategies also apply. Acade-
mia, industry, regulatory authorities, funding agencies,
and patient organizations have to join forces in order to
encourage novel, nonclassical, and nonconventional con-
cepts. The spectrum expands from nearly population-
based approaches for gathering cohorts, and possibly in-
tegrating multidimensional clinical, genetic, environmen-
tal (including nutritional) information (at the expense of
controlled information at all levels) to highly selected
and stratified smaller patient groups with robust, high-
resolution parallel biological information. Those novel
approaches can help to initiate a new era of clinical
studies, different from prototypic double-blind, placebo-
controlled trials. A recent encouraging example is repre-
sented in the field of AD: individuals without any dis-
ease symptoms but genetically predisposed (two copies
of the APoE4 gene) will test 2 drugs targeting the amy-
loid protein [22].
Finally, it is instrumental and most helpful, if not essential,
to integrate the expertise and experiences from different fields
of clinical neuroscience within interdisciplinary panels. This
clearly helps to avoid Bblind sides^ and thus overlooking les-
sons that others already learned from failed or successful
approaches.
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